We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+10.15%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$346M
AUM Growth
+$170M
Cap. Flow
+$163M
Cap. Flow %
46.98%
Top 10 Hldgs %
43.57%
Holding
90
New
39
Increased
14
Reduced
5
Closed
27

Top Buys

1
ACOR
Acorda Therapeutics
ACOR
+$8.81M
2
EW icon
Edwards Lifesciences
EW
+$8.72M
3
BIIB icon
Biogen
BIIB
+$7.91M
4
BLUE
bluebird bio
BLUE
+$7.43M
5
CNMD icon
CONMED
CNMD
+$7.41M

Top Sells

1
CELG
Celgene Corp
CELG
+$6.74M
2
PACB icon
Pacific Biosciences
PACB
+$5.95M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$5.68M
4
SAGE
Sage Therapeutics
SAGE
+$5.34M
5
IHF icon
iShares US Healthcare Providers ETF
IHF
+$4.82M

Sector Composition

1 Healthcare 56.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PACB icon
76
Pacific Biosciences
PACB
$447M
– –
-700,000
Closed -$5.95M
RMD icon
77
ResMed
RMD
$28.9B
– –
-50,000
Closed -$2.89M
SAGE
78
DELISTED
Sage Therapeutics
SAGE
– –
-160,000
Closed -$5.34M
TEVA icon
79
CALL
Teva Pharmaceuticals
TEVA
$37.3B
– –
-100,000
Closed -$5.35M
VRTX icon
80
Vertex Pharmaceuticals
VRTX
$123B
– –
-25,253
Closed -$2.01M
ENDP
81
DELISTED
Endo International plc
ENDP
– –
-24,100
Closed -$678K
SBBP
82
DELISTED
Strongbridge Biopharma plc.
SBBP
– –
-72,726
Closed -$332K
CHMA
83
DELISTED
Chiasma, Inc. Common Stock
CHMA
– –
-75,000
Closed -$687K
GNMK
84
DELISTED
GenMark Diagnostics, Inc
GNMK
– –
-300,000
Closed -$1.58M
PTLA
85
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-100,000
Closed -$2.04M
PTLA
86
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-40,000
Closed -$816K
ACHN
87
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-250,000
Closed -$1.93M
STJ
88
DELISTED
St Jude Medical
STJ
– –
-36,500
Closed -$2.01M
VTAE
89
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
– –
-101,188
Closed -$671K
CYNA
90
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
– –
-151,535
Closed -$1.8M
1 2 3
4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q2 2016 Portfolio in Review

As of Q2 2016, Ghost Tree Capital held 90 positions worth $346M, up 96% from $177M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Ghost Tree Capital deployed $163M of net new capital in Q2 2016, opening 39 new positions and adding to 14 existing holdings. Its largest new stake was Acorda Therapeutics: 2,708 shares worth $8.29M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 62% a quarter earlier.

On the sell side, the largest reduction was Celgene Corp, an estimated $6.74M trimmed.

  • Ghost Tree Capital's largest Q2 2016 buy was Acorda Therapeutics: 2,708 shares worth $8.29M.
  • Ghost Tree Capital added most to Alexion Pharmaceuticals in Q2 2016, an estimated $7.09M increase.
  • Ghost Tree Capital's biggest Q2 2016 reduction was Celgene Corp, cutting an estimated $6.74M.
  • Ghost Tree Capital fully exited Pacific Biosciences in Q2 2016, selling an estimated $5.95M.
  • Ghost Tree Capital's ten largest holdings make up 44% of its $346M portfolio in Q2 2016.
  • Ghost Tree Capital opened 39 new positions and closed 27 in Q2 2016.
  • Ghost Tree Capital's portfolio value rose 96% quarter-over-quarter to $346M.

Based on Ghost Tree Capital's 13F filing for Q2 2016, filed 12 Aug 2016.